Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the updated results of combined ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL) patients with high-risk genomics or an age of 65 years or older (NCT02756897). Results suggest that ibrutinib in combination with venetoclax is an effective chemotherapy-free oral regimen for high-risk previously untreated CLL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.